Collectively, the described features indicate CD8+ TRM cells can display anti-tumor effector responses, but additional investigation is still needed to dissect the role of CD8+ TRM cell subsets expressing different tissue retention molecules, such as CD103, CD49a, and CXCR6. This evidence concerns the gene ITGAE and neoplasm.